Amicus Therapeutics, Inc. (FOLD) Stake Boosted by Palo Alto Investors LP

Palo Alto Investors LP grew its holdings in shares of Amicus Therapeutics, Inc. (NASDAQ:FOLD) by 2.4% in the 1st quarter, according to its most recent disclosure with the SEC. The fund owned 6,147,829 shares of the biopharmaceutical company’s stock after purchasing an additional 141,807 shares during the period. Amicus Therapeutics makes up approximately 4.0% of Palo Alto Investors LP’s holdings, making the stock its 9th largest position. Palo Alto Investors LP’s holdings in Amicus Therapeutics were worth $92,463,000 as of its most recent SEC filing.

Several other hedge funds have also added to or reduced their stakes in the company. Guggenheim Capital LLC lifted its holdings in shares of Amicus Therapeutics by 8.3% during the first quarter. Guggenheim Capital LLC now owns 227,353 shares of the biopharmaceutical company’s stock valued at $3,419,000 after purchasing an additional 17,470 shares during the last quarter. California State Teachers Retirement System lifted its holdings in shares of Amicus Therapeutics by 7.9% during the first quarter. California State Teachers Retirement System now owns 283,912 shares of the biopharmaceutical company’s stock valued at $4,270,000 after purchasing an additional 20,688 shares during the last quarter. Redmile Group LLC lifted its holdings in shares of Amicus Therapeutics by 7.1% during the first quarter. Redmile Group LLC now owns 10,738,658 shares of the biopharmaceutical company’s stock valued at $161,509,000 after purchasing an additional 712,888 shares during the last quarter. Delek Group Ltd. lifted its holdings in shares of Amicus Therapeutics by 218.2% during the first quarter. Delek Group Ltd. now owns 350,000 shares of the biopharmaceutical company’s stock valued at $5,269,000 after purchasing an additional 240,000 shares during the last quarter. Finally, Barclays PLC lifted its holdings in shares of Amicus Therapeutics by 44.2% during the first quarter. Barclays PLC now owns 46,141 shares of the biopharmaceutical company’s stock valued at $693,000 after purchasing an additional 14,135 shares during the last quarter.

In related news, CFO William D. Baird III sold 10,000 shares of the firm’s stock in a transaction on Monday, April 2nd. The shares were sold at an average price of $14.26, for a total transaction of $142,600.00. Following the sale, the chief financial officer now owns 127,662 shares in the company, valued at $1,820,460.12. The transaction was disclosed in a document filed with the SEC, which can be accessed through this link. Also, Director Michael Raab sold 5,000 shares of the firm’s stock in a transaction on Monday, April 16th. The shares were sold at an average price of $14.41, for a total transaction of $72,050.00. Following the sale, the director now owns 10,814 shares in the company, valued at approximately $155,829.74. The disclosure for this sale can be found here. Over the last 90 days, insiders sold 140,000 shares of company stock valued at $2,132,800. 2.90% of the stock is owned by insiders.

Several equities analysts have recently issued reports on FOLD shares. Zacks Investment Research upgraded shares of Amicus Therapeutics from a “sell” rating to a “hold” rating in a report on Thursday, May 10th. ValuEngine upgraded shares of Amicus Therapeutics from a “buy” rating to a “strong-buy” rating in a report on Wednesday, May 2nd. BidaskClub lowered shares of Amicus Therapeutics from a “strong-buy” rating to a “buy” rating in a report on Friday, June 1st. Finally, Cowen restated a “buy” rating and issued a $22.00 price objective on shares of Amicus Therapeutics in a report on Tuesday, May 8th. Three investment analysts have rated the stock with a hold rating, six have given a buy rating and one has assigned a strong buy rating to the company. The company presently has a consensus rating of “Buy” and a consensus target price of $19.06.

Shares of Amicus Therapeutics opened at $16.07 on Thursday, according to MarketBeat.com. The company has a debt-to-equity ratio of 0.32, a quick ratio of 4.15 and a current ratio of 4.21. The stock has a market cap of $2.89 billion, a PE ratio of -5.50 and a beta of 1.53. Amicus Therapeutics, Inc. has a 12-month low of $8.45 and a 12-month high of $17.40.

Amicus Therapeutics (NASDAQ:FOLD) last issued its earnings results on Tuesday, May 8th. The biopharmaceutical company reported ($0.28) EPS for the quarter, topping the Zacks’ consensus estimate of ($0.36) by $0.08. Amicus Therapeutics had a negative net margin of 563.98% and a negative return on equity of 60.09%. The business had revenue of $16.70 million for the quarter, compared to the consensus estimate of $16.78 million. sell-side analysts expect that Amicus Therapeutics, Inc. will post -1.26 EPS for the current year.

About Amicus Therapeutics

Amicus Therapeutics, Inc, a biotechnology company, engages in the discovery, development, and commercialization of medicines for various rare and orphan diseases. The company offers migalastat HCl, an orally administered small molecule pharmacological chaperone for the treatment of Fabry disease. It is also conducting a Phase 1/2 clinical study of ATB200-02 to investigate in patients with pompe disease.

Want to see what other hedge funds are holding FOLD? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Amicus Therapeutics, Inc. (NASDAQ:FOLD).

Institutional Ownership by Quarter for Amicus Therapeutics (NASDAQ:FOLD)

Receive News & Ratings for Amicus Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Amicus Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply